Optimizing Lung Cancer Radiation Therapy: A systematic review of Multifactorial Risk Assessment for Radiation-Induced Lung Toxicity
Lung cancer remains a global health challenge, accounting for over two million new cases annually and one of the highest mortality rates among all cancers in 2020 [1]. Non-small-cell lung cancer (NSCLC) represents approximately 80% of total cases. In 2010, between 15% and 25% of lung cancer patients presented with inoperable tumors at diagnosis, with concurrent chemoradiotherapy (CCRT) using platinum as the standard of care for this population facing a NSCLC or a small-cell lung cancer (SCLC); both taking benefit from this therapeutic [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Rayan Bensenane, Sylvie Helfre, Kim Cao, Matthieu Carton, Laurence Champion, Nicolas Girard, Matthieu Glorion, Thibaut Vieira, Waisse Waissi, Gilles Crehange, Arnaud Beddok Tags: Anti-tumour Treatment Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Radiation Therapy | Small Cell Lung Cancer | Toxicology